NLS Reinstated and Recapitalised

The Company was recapitalised and reinstated to official quotation on the ASX on 14 March 2011. Completion of the recapitalisation through the capital raising of $2.5 million restructured the Company's issued capital.

Liberian Gold & Diamond Project

Narhex Life Sciences Limited has entered into an Agreement with Golden Saint Australia Limited to acquire its interest in Golden Saint Liberia Limited, a registered holder and beneficial owner of 80% of mining tenements in Liberia.

READ MORE

ResApp Health Limited

Narhex Life Sciences Limited has been renamed ResApp Health Limited after acquiring 100% of ResApp Diagnostics Pty Ltd.

ResApp, through the exclusive licence it has been granted by the University of Queensland (UQ), is developing smart phone medical applications for the diagnosis and management of respiratory disease. The technology is based on a machine learning algorithm that uses sound alone without the need for additional hardware to diagnose and measure the severity of a respiratory condition. The algorithm has been successfully tested for pneumonia and asthma diagnosis in a clinical proof of concept study of 91 patients by UQ through funding from the Bill and Melinda Gates Foundation.